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Background: The authors examined whether milrinone and levosimendan could exert cardiac postconditioning
effects in rats under normoglycemia and hyperglycemia, and whether the effects could be mediated by
mitochondrial permeability transition pore (mPTP).
Methods: Wistar rats underwent 30-min coronary artery occlusion followed by 2-h reperfusion. The rats received
milrinone or levosimendan just before reperfusion under normoglycemic or hyperglycemic conditions with or
without atractyloside, an mPTP opener.
Results: Under normoglycemia, both 30 μg/kg milrinone (29 ± 12%) and 10 μg/kg levosimendan (33 ± 13%)
reduced infarct size compared with that in the control (58 ± 7%). Under hyperglycemia, milrinone (34 ± 13%)
reduced infarct size at the same dose as under normoglycemia. In contrast, neither 10 nor 30 μg/kg levosimendan
protected hyperglycemic hearts, and only 100 μg/kg levosimendan (32 ± 9%) reduced infarct size compared with
that in the hyperglycemic control (58 ± 13%). All of these cardioprotective effects under normoglycemia and
hyperglycemia are abolished by atractyloside.
Conclusion: Milrinone and levosimendan exert postconditioning effects via inhibition of mPTP opening.
Hyperglycemia raises the threshold of levosimendan-induced postconditioning, while milrinone-induced
postconditioning is not influenced by hyperglycemia.
Keywords: Hyperglycemia, Postconditioning, Myocardial Infarction, Milrinone, Levosimendan, Mitochondrial perme-
ability transition pore
Introduction
Hyperglycemia (HG) is frequently observed in patients
with acute myocardial ischemic events such as myocar-
dial infarction or the usage of cardiopulmonary bypass
in cardiac surgery. Many studies have demonstrated the
association between HG and increased mortality after
acute myocardial infarction [1]. One possible cause of
high mortality may be poor cardioprotective strategies
under HG. HG was shown to abolish cardioprotection
induced by ischemic and pharmacological precondition-
ing (PreC) [2,3]. Postconditioning (PostC) is more likely
than PreC to be feasible as a clinical application, and
may be useful in unpredictable myocardial ischemia-
reperfusion injury. It was also reported that HG abol-
ished both ischemic and pharmacological PostC [4-6].
To save the ischemic myocardium exposed to HG envir-
onment, it is essential to investigate the effective PostC
maneuver under HG.
Milrinone, a phosphodiesterase 3 inhibitor (PDE-I),
and levosimendan, a calcium sensitizer, are relatively
new types of inotropic agent and known to facilitate
functional recovery from myocardial ischemia-reperfu-
sion injury (e.g., cardiac surgery under cardiopulmonary
bypass and conditions after cardiopulmonary resuscita-
tion), and could lead to preserved perfusion of major
organs after myocardial reperfusion [7-10]. At the
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occurs during post-ischemic reperfusion, and could
cause cardiac arrhythmias or myocardial stunning. PDE-
I causes the activation of cyclic adenosine monopho-
sphate (cAMP) and protein kinase A (PKA), resulting in
altered calcium handling by sarcoplasmic reticulum (SR)
[11]. Levosimendan improves cardiac contractility with-
out change in intracellular calcium [12]. Thus, the prop-
erties of these drugs are favorable for myocardial post-
ischemic reperfusion period.
Levosimendan has a vasodilatory effect via opening of
ATP-sensitive potassium (KATP) channels in the plasma
membrane of vascular smooth muscle cells, and also
activates myocardial mitochondrial KATP (m-KATP)
channels and exerts PreC effect against ischemia-reper-
fusion injury [13]. Besides PreC, PostC induced by levo-
simendan has been reported in recent years and it has
been suggested that m-KATP channels and phosphatidy-
linositol 3-kinase (PI3K) are involved in the mechanisms
[14,15]. PDE-Is also has PreC properties via activation
of the cAMP/PKA pathway independent of protein
kinase C (PKC) and m-KATP channels [16,17]. Recently,
it was shown that milrinone and levosimendan treat-
ment started prior to reperfusion exerted effects to limit
right ventricular infarct size [18].
HG normally elevates intracellular ATP, and m-KATP
channel opening-dependent cardioprotective effects
would be abolished under HG [19]. Kehl et al. [3]
showed that moderate hyperglycemia (blood glucose
level of 300 mg/dl) blocked the protective effects of 0.5
minimum alveolar concentration (MAC) but not 1.0
MAC isoflurane. Tsang et al. [20] showed that three-
cycle but not one-cycle ischemic PreC reduced myocar-
dial infarct size, and stated that it seems necessary to
increase the ischemic PreC stimulus to achieve the
threshold for cardioprotection against diabetic myocar-
dium. PDE-I-induced PostC, which is independent of
m-KATP channels, would not be impaired by HG.
Multiple lines of evidence suggest that the mitochon-
drial permeability transition pore (mPTP) is a key end
effector of ischemic and pharmacological PostC [21],
and the important link between Reperfusion Injury Sal-
vage Kinases (RISK)/Survivor Activating Factor
Enhancement (SAFE) pathways and mPTP has also been
suggested [21,22]. Under HG, adequate mPTP closing
maneuver would be essential for myocardial infarct size
reduction [5].
In the present study, we hypothesized that HG would
raise the threshold of levosimendan-induced PostC,
which is mediated by m-KATP channels, and we also
examined whether milrinone- and levosimendan-
induced PostC could be mediated by the inhibition of
mPTP opening.
Materials and methods
All experimental procedures and protocols described in
t h i ss t u d yw e r ea p p r o v e db yt h eI n s t i t u t i o n a lA n i m a l
Care and Use Committee of the Nagasaki University
School of Medicine.
Drugs
Milrinone was purchased from Astellas Pharma Co.
(Tokyo, Japan). Levosimendan, atractyloside, and 2,3,5-
triphenyltetrazolium chloride (TTC) were purchased
from Sigma (St. Louis, MO, USA).
General Preparation
The instrumental methods used were as described in
our previous report [17]. Male Wistar rats weighing
between 250 and 450 g were anesthetized with sodium
pentobarbital (a 50 mg/kg intraperitoneal bolus followed
by an intravenous infusion at 10-20 mg/kg/h). The rats
were adequately sedated to ensure that pedal and pal-
pebral reflexes were absent throughout the experimental
protocol. Catheters were inserted into the right jugular
vein and the right carotid artery for fluid or drug
administration and measurement of arterial blood pres-
sure, respectively. After tracheotomy, the trachea was
intubated with a cannula connected to a small animal
ventilator (model SAR-830 CWE, PA, USA), and the
lungs were ventilated with pure oxygen. Arterial blood
gas pH was maintained within a physiological range by
adjusting the respiratory rate and tidal volume through-
out the experiment. A left thoracotomy was performed
in the fifth intercostal space, and the pericardium was
opened. A 7-0 prolene ligature was placed around the
proximal left anterior descending coronary artery (LAD)
and vein in the area immediately below the left atrial
appendage. The ends of the suture were threaded
through a small plastic tube to form a snare for reversi-
ble LAD occlusion. Coronary artery occlusion was pro-
duced by clamping the snare onto the epicardial surface
of the heart and was confirmed by the appearance of
epicardial cyanosis. Reperfusion was achieved by loosen-
ing the snare and was verified by observing an epicardial
hyperemic response. Hemodynamics were continuously
monitored with a transducer (blood pressure monitor
link sck-9082; Becton Dickinson, Tokyo, Japan) and an
AP-641G blood pressure amplifier (Nihon-Kohden,
Tokyo, Japan) and shown on a polygraph system
(Nihon-Kohden).
Experimental Protocol
The experimental design used in the current investiga-
tion is illustrated in Figure 1. All rats underwent 30-
min coronary artery occlusion followed by 2-h
reperfusion.
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levosimendan-induced PostC under normoglycemia (NG)
The experiments were performed under NG. Wistar rats
were allocated to one of 5 groups. The rats received sal-
i n e( g r o u pC O N ;n=1 4 ) ,m i l r i n o n ea t1 0μg/kg (group
MIL10; n = 8), milrinone at 30 μg/kg (group MIL30; n
=9 ) ,l e v o s i m e n d a na t3μg/kg (group LEV3; n = 7), or
levosimendan at 10 μg/kg (group LEV10; n = 9). These
drugs were administered as i.v. bolus just prior to
reperfusion.
Protocol 2: The threshold of milrinone- and
levosimendan-induced PostC under HG
The experiments were performed under HG. Wistar rats
were allocated to one of 5 groups. To produce HG, rats
received 50% glucose intravenously starting 5 min before
ischemia and lasting until 60 min after reperfusion. The
target blood glucose level was 300 mg/dl throughout the
experiment. To test the drugs, the rats received saline
(group HG CON; n = 10), milrinone at 30 μg/kg (group
HG MIL30; n = 7), levosimendan at 10 μg/kg (group HG
LEV10; n = 9), levosimendan at 30 μg/kg (group
HG LEV30; n = 7), or levosimendan at 100 μg/kg (group
HG LEV100; n = 7) just prior to reperfusion. The doses
were set on the basis of the results of protocol 1.
Protocol 3: The role of mPTP in milrinone- and
levosimendan-induced postconditioning
Atractyloside, an mPTP opener (5 mg/kg), was adminis-
tered intravenously 5 min before reperfusion, and the
protective doses of milrinone or levosimendan were
administered just before reperfusion under NG and HG.
The doses of atractyloside were set on the basis of pre-
vious studies [23,24]. The protective doses of test drugs
w e r es e to nt h eb a s i so fp r o t o c o l s1a n d2a sf o l l o w s :
milrinone at 30 μg/kg and levosimendan at 10 μg/kg
under NG, and milrinone at 30 μg/kg and levosimendan
at 100 μg/kg under HG.
Blood Glucose Measurement
Blood samples were collected to measure blood glu-
cose in all rats. The blood glucose level was deter-
mined by the glucose oxidase method using a Glutest
sensor and Glutest Ace (Sanwa Kagaku Kenkyusho,
Nagoya, Japan). Samples were taken before starting
glucose administration, just before ischemia (after
Figure 1 A schematic illustration of the experimental protocols.
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reperfusion, and 1 and 2 hr after reperfusion.
Determination of Infarct Size
At the end of the experiment, the LAD was reoccluded.
Patent blue dye was administered intravenously to stain
the normal region of the left ventricle (LV), and the
heart was rapidly excised. Excess LV tissue was removed
and cut into approximately 10 cross-sectional slices of
equal thickness. The nonstained LV area at risk (AAR)
was physically separated from the blue-stained LV nor-
mal zone, and incubated at 37°C for 15 min in 1% TTC
in 0.1 M phosphate buffer adjusted to pH 7.4. The tis-
sue slices were fixed overnight in 10% formaldehyde. LV
tissues after TTC staining are shown in Figure 2. TTC
stains living tissue deep red, but necrotic tissue is TTC-
negative and appears white. Each slice was scanned at
1200 dpi with a commercial scanner (Canoscan LiDE
60; Canon, Japan), and infarcted and noninfarcted areas
were measured by one observer blinded to the rat
groups using an image analysis program. Myocardial
infarct size is expressed as a percentage of the AAR.
Statistical Analysis
Statistical analysis of hemodynamic data and blood glu-
cose concentrations within and between groups was per-
formed with analysis of variance for repeated measures
followed by Dunnett’s test. Inter-group differences in
body weight, age, LV weight, AAR weight, the ratio of
AAR to LV, and the ratio of infarct size to AAR were
analyzed using one-way analysis of variance followed by
the Student-Newman-Keuls test. Statistical significance
was defined as P < 0.05. All values are expressed as
mean ± SD. Statistical analysis was performed using
SPSS 15.0 software (SPSS Japan, Tokyo, Japan) or
GraphPad Prism 5.0 (GraphPad Software, San Diego,
CA).
Results
There were no significant differences in body weight or
age among the groups. One hundred and fifty-one rats
were used, with 124 successful myocardial infarct size
experiments being achieved. Ten rats were excluded as
a result of technical difficulties with the experimental
preparation. Malignant ventricular arrhythmias devel-
oped in 17 other rats before completion of the experi-
ment. Two in the CON group, 1 in the MIL10 group, 2
in the LEV3 group, 1 in the LEV10 group, 1 in the HG
CON group, 2 in the HG MIL30 group, 2 in the HG
LEV10 group, 1 in the HG LEV30 group, 1 in the ATR .
g r o u p ,2i nt h eM I L 3 0+A T Rg r o u p ,1i nt h eL E V 1 0+
ATR group, and 1 in the HG LEV100 + ATR group; no
differences in incidence of arrhythmic events were
observed among groups. These rats were excluded from
further analysis.
Hemodynamics
Hemodynamic variables are summarized in Table 1 and
2. No significant differences in mean arterial pressure
and heart rate were observed between the experimental
groups at baseline. In levosimendan-treated groups,
mean arterial pressure showed a tendency to decrease
transiently during the early reperfusion period. Heart
rate increased in the LEV10 group and HG LEV100
group at 2hr after reperfusion as compared with that in
the CON group.
Infarct Size
LV weight, AAR weight, and the ratio of AAR to total
LV mass were similar among the groups (Table 3).
Infarct size expressed as a percentage of area at risk is
s h o w ni nF i g u r e3 ,4 ,5 .A ss h o w ni nF i g u r e3 ,i nN G
rats, 30 μg/kg milrinone and 10 μg/kg levosimendan
reduced infarct size compared with that in the control
(MIL30: 29 ± 12%; LEV10: 33 ± 13%; CON: 58 ± 7%).
In contrast, low-dose groups (10 μg/kg milrinone and 3
μg/kg levosimendan) did not show reduction of infarct
size (MIL10: 55 ± 10%; LEV3: 55 ± 16%). As shown in
Figure 4, in HG rats, 100 μg/kg but not 10 μg/kg or 30
μg/kg levosimendan reduced infarct size compared with
that in the control (HG LEV100: 32 ± 9%; HG LEV10:
55 ± 15%; HG LEV30: 57 ± 13%;HG CON: 58 ± 13%).
In contrast, 30 μg/kg milrinone showed similar degrees
of infarct size reduction in NG and HG rats (HG
Figure 2 Left ventricular tissues after 2,3,5-triphenyltetrazolium
chloride staining. Non-ischemic areas have been cut off. Areas at
risk are stained red and necrotic areas appear pale.
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blocked the beneficial effects of both milrinone and
levosimendan (LEV10 + ATR: 58 ± 11%; MIL30 + ATR:
60 ± 9%; HG LEV100 + ATR: 62 ± 13%; HG MIL30 +
ATR: 62 ± 13%). Atractyloside alone did not affect
infarct size (ATR: 55 ± 13%).
Blood Glucose Measurement
Blood glucose concentrations are summarized in Table
4. No significant differences in blood glucose concen-
trations were observed between the experimental
groups at baseline. After starting administration of
50%-glucose solution, rats in HG groups had
Table 1 Mean Arterial Pressure
Number Baseline Preocclusion Occlusion
30 min
Reperfusion
5 min 30 min 1 hr 2 hr
MAP (mmHg)
CON 14 99 ± 24 97 ± 14 93 ± 20 95 ± 26 109 ± 28 107 ± 31 100 ± 36
MIL10 8 91 ± 24 88 ± 26 91 ± 23 84 ± 25 100 ± 26 104 ± 20 107 ± 15
MIL30 9 98 ± 14 83 ± 14 91 ± 16 88 ± 22 103 ± 17 99 ± 30 99 ± 31
LEV3 7 97 ± 20 95 ± 16 84 ± 27 87 ± 12 92 ± 16 99 ± 14 106 ± 14
LEV10 9 90 ± 16 84 ± 13 79 ± 28* 80 ± 23* 89 ± 32 93 ± 26 96 ± 22
HGCON 10 109 ± 21 107 ± 23 93 ± 20 92 ± 23 102 ± 26 110 ± 23 112 ± 20
HG MIL30 7 101 ± 13 102 ± 12 92 ± 13 93 ± 11 101 ± 14 109 ± 18 118 ± 19
HG LEV10 9 101 ± 16 91 ± 9 85 ± 10 84 ± 11 94 ± 15 104 ± 17 108 ± 18
HG LEV30 7 105 ± 21 97 ± 11 96 ± 18 93 ± 15 93 ± 12 106 ± 9 104 ± 18
HG LEV100 7 103 ± 18 109 ± 12 79 ± 12* 81 ± 9* 84 ± 13 96 ± 14 94 ± 21
ATR 6 103 ± 13 96 ± 13 108 ± 11 107 ± 15 113 ± 19 113 ± 16 116 ± 12
MIL30 + ATR 8 101 ± 14 93 ± 21 97 ± 14 97 ± 15 101 ± 15 101 ± 16 102 ± 11
LEV10 + ATR 7 87 ± 15 85 ± 15 97 ± 22 95 ± 17 97 ± 24 98 ± 20 96 ± 18
HG MIL30 + ATR 7 98 ± 20 95 ± 17 98 ± 19 100 ± 20 103 ± 21 103 ± 17 88 ± 17
HG LEV100 + ATR 9 93 ± 14 97 ± 18 89 ± 21 88 ± 17 98 ± 21 103 ± 23 101 ± 25
Data are mean ± SD.
MAP = mean arterial pressure; CON = control; MIL10 or 30 = 10 or 30 μg/kg milrinone; LEV 3, 10, 30 or 100 = 3, 10, 30 or 100 μg/kg levosimendan; HG =
hyperglycemia; ATR = atractyloside.
*Significantly (P < 0.05) different from baseline.
Table 2 Heart Rate
Number Baseline Preocclusion Occlusion
30 min
Reperfusion
5 min 30 min 1 hr 2 hr
HR (mmHg)
CON 14 389 ± 39 383 ± 43 375 ± 46 381 ± 51 376 ± 52 374 ± 56 342 ± 68*
MIL10 8 352 ± 51 354 ± 58 345 ± 68 340 ± 64 338 ± 58 339 ± 70 340 ± 72
MIL30 9 381 ± 66 379 ± 65 362 ± 24 372 ± 41 346 ± 61 349 ± 80 335 ± 91*
LEV3 7 370 ± 20 367 ± 15 339 ± 40 356 ± 31 350 ± 38 340 ± 40 338 ± 52
LEV10 9 408 ± 37 396 ± 28 387 ± 45 390 ± 41 395 ± 42 399 ± 45 405 ± 56†
HGCON 10 394 ± 55 377 ± 64 397 ± 40 390 ± 70 391 ± 67 380 ± 76 371 ± 114
HG MIL30 7 366 ± 44 365 ± 44 377 ± 33 381 ± 36 382 ± 50 363 ± 73 373 ± 82
HG LEV10 9 402 ± 35 389 ± 35 364 ± 18 374 ± 15 367 ± 32 366 ± 49 366 ± 56
HG LEV30 7 372 ± 49 376 ± 47 361 ± 45 371 ± 46 364 ± 38 359 ± 35 348 ± 50
HG LEV100 7 433 ± 24 421 ± 32 400 ± 30 413 ± 29 394 ± 45 390 ± 57 402 ± 29†
ATR 6 379 ± 21 372 ± 15 359 ± 17 367 ± 24 369 ± 29 365 ± 33 347 ± 44
MIL30 + ATR 8 377 ± 50 386 ± 34 363 ± 34 372 ± 37 379 ± 40 358 ± 41 367 ± 35
LEV10 + ATR 7 364 ± 34 382 ± 30 335 ± 34 345 ± 45 339 ± 51 331 ± 43 336 ± 52
HG MIL30 + ATR 7 386 ± 53 394 ± 48 396 ± 38 411 ± 46 404 ± 49 407 ± 48 377 ± 60
HG LEV100 + ATR 9 412 ± 27 411 ± 47 387 ± 32 399 ± 33 379 ± 50 384 ± 54 375 ± 47
Data are mean ± SD.
HR = heart rate; CON = control; MIL10 or 30 = 10 or 30 μg/kg milrinone; LEV 3, 10, 30 or 100 = 3, 10, 30 or 100 μg/kg levosimendan; HG = hyperglycemia; ATR =
atractyloside.
*Significantly (P < 0.05) different from baseline. †Significantly (P < 0.05) different from CON.
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rats in NG groups.
Discussion
The present study is, to our knowledge, the first to demon-
strate that milrinone-induced PostC protects the heart
under HG at the same dose as under NG, while levosimen-
dan-induced PostC requires an increased dose under HG.
Our results also demonstrate that all of these cardioprotec-
tive effects in NG and HG are mediated by mPTP.
Cardioprotective Signaling Pathways in HG Conditions
It is well known that acute HG condition attenuates
endogenous cardioprotective phenomena by ischemic/
pharmacological interventions. Ischemic/pharmacologi-
c a lP r e Ca n dP o s t Cc o u l di n h i b i tm P T Po p e n i n ga t
reperfusion through m-KATP channels and complex sig-
nal transduction pathways such as PI3K-Akt, p42/p44
extracellular signal-regulated kinases (ERK 1/2), glyco-
gen synthase kinase-3beta (GSK-3beta), endothelial
nitric oxide synthase (eNOS), and PKC [21,22]. Reactive
oxygen species (ROS) generated by the mitochondrial
electron transport chain during ischemic/pharmacologi-
cal PreC stimulus have been shown to activate m-KATP
channels that confer protection of ischemic myocar-
dium, and the ROS scavengers abolish cardioprotection
[25]. Kehl et al. [26] reported that acute HG abolishes
isoflurane-induced PreC, but a ROS scavenger, N-acetyl-
cysteine, restores these beneficial effects. They suggested
that excessive quantities of ROS generated under HG
impair isoflurane-induced activation of m-KATP chan-
nels. Raphael et al. [4] showed that acute HG inhibits
isoflurane-induced PostC, and stated that this effect
seems to be mediated via inhibition of Akt and eNOS
activation. Acute HG and diabetes are different patholo-
gical conditions. Ku et al. [27] reported that HG-
induced ROS generation in cardiomyocytes is linked to
diabetic cardiomyopathy through GATA binding protein
4 phosphorylation and a higher expression of cardiac
troponin I. Kageyama et al. [28] found that HG up-regu-
lated death receptor expression, coupled with increased
tumor necrosis factor (TNF)-alpha secretion, promoted
endothelial cell apoptosis, and suggested that it is
Table 3 Left-Ventricular Area at Risk
Number Area at Risk/Left Ventricle (%)
CON 14 57 ± 8
MIL10 8 51 ± 9
MIL30 9 52 ± 7
LEV3 7 56 ± 5
LEV10 9 51 ± 5
HG CON 10 50 ± 4
HG MIL30 7 53 ± 3
HG LEV10 9 52 ± 7
HG LEV30 7 56 ± 5
HG LEV100 7 50 ± 10
ATR 6 51 ± 4
MIL30 + ATR 8 48 ± 5
LEV10 + ATR 7 48 ± 8
HG MIL30 + ATR 7 48 ± 8
HG LEV100 + ATR 9 51 ± 4
Data are mean ± SD.
CON = control; MIL10 or 30 = 10 or 30 μg/kg milrinone; LEV 3, 10, 30 or 100
= 3, 10, 30 or 100 μg/kg levosimendan; HG = hyperglycemia; ATR =
atractyloside.
Figure 3 Myocardial infarct size expressed as a percentage of the left ventricular area at risk in protocol 1. CON = control; MIL10, 30 =
10 or 30 μg/kg milrinone, LEV3, 10 = 3 or 10 μg/kg levosimendan. Data are mean ± SD. *Significantly (P < 0.05) different from CON.
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and the development of ischemic heart disease in dia-
betes. Therefore, it is necessary to consider the glycation
of intracellular proteins and the effects of complications
for patients with diabetes. On the other hand, the inhi-
bitory effects of diabetes on PreC/PostC similar to that
of acute HG have also been reported. Tsang et al. [20]
showed that three-cycle but not one-cycle ischemia
Figure 4 Myocardial infarct size expressed as a percentage of the left ventricular area at risk in protocol 2. HG = hyperglycemia; CON =
control; MIL30 = 30 μg/kg milrinone, LEV10, 30 or 100 = 10, 30 or 100 μg/kg levosimendan. Data are mean ± SD. *Significantly (P < 0.05)
different from HG-CON.
Figure 5 Myocardial infarct size expressed as a percentage of the left ventricular area at risk in protocol 2. CON = control; HG =
hyperglycemia; ATR = atractyloside; MIL30 = 30 μg/kg milrinone, LEV100 = 100 μg/kg levosimendan. Data are mean ± SD. *Significantly (P <
0.05) different from CON. §Significantly (P < 0.05) different from HG-CON. †Significantly (P < 0.05) different from the group without ATR.
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commensurate with significant Akt phosphorylation
after three cycles of ischemia PreC. Diabetes inhibits
erythropoietin- and morphine-induced activation of
PI3K-Akt, ERK 1/2, and inhibition of GSK-3beta, and
attenuates PostC [29,30]. They also showed that a GSK-
3beta inhibitor, SB216763, reduced myocardial infarct
size in diabetic rats as well as in non-diabetic rats, and
suggested that the mechanism of diabetes-induced
attenuation could be due to impairment of protective
upstream signaling pathways such as PI3K-Akt and ERK
1/2. Thus poor cardioprotective strategies for both acute
HG and diabetes would be derived from the inhibition
of the intracellular signaling pathways involved in
ischemic and pharmacological PreC and PostC.
Difference between Protective Effects of Levosimendan
and Milrinone under HG
In the present study, levosimendan exerted the PostC
effect under HG at a dose ten times higher than the
dose under NG. Kersten et al. [19] showed that both 2.5
and 5 μg/kg diazoxide, an m-KATP channel opener, had
PreC effects under NG, and that only 5 μg/kg but not
2.5 μg/kg diazoxide reduced myocardial infarct size
under acute HG. They suggested that m-KATP channel
opening-dependent cardioprotective effects might be
attenuated under HG, and thus, increase in the dosage
is required. Hönisch et al. [15] showed that levosimen-
dan just prior to reperfusion significantly reduced myo-
cardial infarct size, and this beneficial effect was blocked
by 5-hydroxydecanoic acid, an m-KATP channel blocker.
Thus, it is likely that HG increases the threshold of
levosimendan-induced PostC, resulting from the
attenuation of the m-KATP channel opening-dependent
cardioprotective effect. In contrast to levosimendan, mil-
rinone-induced PostC protects hearts under HG at the
same dose as under NG. Our previous study showed
that preischemic administration of olprinone, a PDE-I,
reduces myocardial infarct size in type 2 diabetic rats to
t h es a m ee x t e n ta si nn o n - d i a b e t i cr a t s ,a n dt h a to l p r i -
none-induced PreC is independent of m-KATP channels
and PKC [17]. Our previous study also showed that
levosimendan-induced PostC was dependent on m-KATP
channels and PKC; however, milrinone-induced PostC
has been suggested to be independent of m-KATP chan-
nels and PKC [31,32]. We speculate that milrinone has
a different protective pathway leading to mPTP closure
independently of m-KATP channels and exerts PostC
effects under HG as well as NG.
Mechanisms leading to mPTP and Cardioprotection
The present results show that levosimendan-induced
PostC is mediated by mPTP. Multiple lines of evidence
indicate that the mPTP is a key end effector of ischemic
and pharmacological PostC [21]. In vitro studies using
isolated mitochondria have suggested that the opening
of m-KATP channels leads to mPTP closure [22]. From
this report and our results, the mechanism of levosi-
mendan-induced PostC would involve m-KATP channel
and mPTP. The present study also shows that atractylo-
side, an mPTP opener, prevents milrinone-induced
PostC, indicating that this protective effect would be
Table 4 Blood Glucose Concentrations (mg/dl)
Number Baseline Preocclusion Occlusion
30 min
Reperfusion
1h r 2h r
CON 14 92 ± 23 89 ± 19 109 ± 40 129 ± 43 111 ± 34
MIL10 8 114 ± 75 105 ± 52 132 ± 60 124 ± 56 105 ± 70
MIL30 9 93 ± 23 82 ± 20 107 ± 51 98 ± 46 79 ± 29
LEV3 7 116 ± 40 89 ± 24 138 ± 66 120 ± 80 106 ± 49
LEV10 9 99 ± 39 97 ± 28 122 ± 51 113 ± 33 101 ± 41
HG CON 10 90 ± 16 355 ± 121*
† 286 ± 137*
† 361 ± 140*
† 273 ± 144*
†
HG MIL30 7 87 ± 16 343 ± 95*
† 351 ± 62*
† 295 ± 150*
† 246 ± 140*
†
HG LEV10 9 88 ± 17 320 ± 97*
† 311 ± 120*
† 321 ± 142*
† 285 ± 161*
†
HG LEV30 7 98 ± 32 341 ± 83*
† 390 ± 99*
† 313 ± 124*
† 293 ± 153*
†
HG LEV100 7 110 ± 45 447 ± 84*
† 394 ± 113*
† 408 ± 140*
† 385 ± 161*
†
ATR 6 82 ± 38 87 ± 25 93 ± 14 87 ± 25 85 ± 12
MIL30 + ATR 8 80 ± 27 80 ± 15 101 ± 49 90 ± 58 77 ± 47
LEV10 + ATR 7 100 ± 32 100 ± 36 124 ± 57 147 ± 94 123 ± 80
HG MIL30 + ATR 7 74 ± 29* 317 ± 70*
† 376 ± 31*
† 293 ± 191*
† 241 ± 197*
†
HG LEV100 + ATR 9 76 ± 13 341 ± 145*
† 379 ± 106*
† 381 ± 149*
† 311 ± 131*
†
Data are mean ± SD.
CON = control; MIL10 or 30 = 10 or 30 μg/kg milrinone; LEV 3, 10, 30 or 100 = 3, 10, 30 or 100 μg/kg levosimendan; HG = hyperglycemia; ATR = atractyloside.
*Significantly (P < 0.05) different from baseline. †Significantly (P < 0.05) different from CON.
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preischemic administration of olprinone could confer
cardioprotection, and that this cardioprotective effect
could be mediated by the activation of PI3K-Akt or by
the inhibition of mPTP during early reperfusion [23]. In
addition, recent studies have shown that milrinone- and
levosimendan-induced PostC increases the level of phos-
phorylation of Akt [33,34]. The experimental study by
Davidson et al. [35] provided evidence that the activa-
tion of the PI3K-Akt pathway is linked to the inhibition
of mPTP opening. They showed that pharmacological
inhibition of either PI3K or Akt abrogated the effect of
insulin to prevent mPTP opening in rat cardiomyocytes,
and that over-expression of Akt in a cardiac-derived cell
line delayed mPTP opening.
Limitations of the study
In clinical studies, myocardial ischemia is an important
prognosis-exacerbating factor in both the diabetic and non-
diabetic states of patients who received reperfusion therapy
[36]. In addition, adverse events in terms of cardiovascular
risk modification are known to occur in both acute and
chronic HG [37]. Therefore, the present study was planned
and conducted, with a focus on acute HG. However,
patients in the clinical setting are in a chronic HG state
because of diabetes, making it necessary to consider the
glycation of intracellular proteins and the effects of compli-
cations such as diabetic cardiomyopathy and endothelial
dysfunction. Thus, further studies are needed to apply the
results of this experimental study to the clinical setting.
Conclusions
We have demonstrated that milrinone and levosimendan
exert PostC via inhibition of mPTP opening, and that
HG raises the threshold of levosimendan-induced PostC,
while milrinone-induced PostC is not influenced by HG.
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